nVerses Capital’s Cardlytics CDLX Stock Holding History

nVerses Capital’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-510	Closed	-$16.3K	–	152
2024 Q3	$16.3K	Buy	+510	New	+$28.3K	0.01%	833

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return

WPM

Worldly Partners Management Needham, Massachusetts $118M AUM 19.19% 1-Year Est. Return

MFS

Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

nVerses Capital's CDLX Position: Q4 2024 in Review

nVerses Capital sold out of Cardlytics (CDLX) in Q4 2024, closing a stake of 510 shares — an estimated $16.3K sold.

nVerses Capital first reported a position in CDLX in Q3 2024 and held it in 1 quarter. The position peaked at $16.3K in Q3 2024. 108 funds tracked by Wall St. Rank hold CDLX as of Q4 2024.

nVerses Capital reported no remaining Cardlytics position as of Q4 2024 after selling out during the quarter.
nVerses Capital sold 510 Cardlytics shares in Q4 2024, an estimated $16.3K.
nVerses Capital first reported a position in Cardlytics in Q3 2024 and held it in 1 quarter.
nVerses Capital's Cardlytics position peaked at $16.3K in Q3 2024.
108 funds tracked by Wall St. Rank held Cardlytics as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.